JP2015512246A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512246A5
JP2015512246A5 JP2015500675A JP2015500675A JP2015512246A5 JP 2015512246 A5 JP2015512246 A5 JP 2015512246A5 JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015512246 A5 JP2015512246 A5 JP 2015512246A5
Authority
JP
Japan
Prior art keywords
item
domain
polypeptide
protein
items
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032686 external-priority patent/WO2013138795A1/en
Publication of JP2015512246A publication Critical patent/JP2015512246A/ja
Publication of JP2015512246A5 publication Critical patent/JP2015512246A5/ja
Pending legal-status Critical Current

Links

JP2015500675A 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法 Pending JP2015512246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611493P 2012-03-15 2012-03-15
US61/611,493 2012-03-15
PCT/US2013/032686 WO2013138795A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Publications (2)

Publication Number Publication Date
JP2015512246A JP2015512246A (ja) 2015-04-27
JP2015512246A5 true JP2015512246A5 (https=) 2016-05-12

Family

ID=49161881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500675A Pending JP2015512246A (ja) 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法

Country Status (6)

Country Link
US (1) US20150266939A1 (https=)
EP (1) EP2825561A4 (https=)
JP (1) JP2015512246A (https=)
AU (1) AU2013231851A1 (https=)
CA (1) CA2867188A1 (https=)
WO (1) WO2013138795A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX
WO2015069587A2 (en) * 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
SG10201811729PA (en) * 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
JP2017504325A (ja) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス，インコーポレイテッド バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法
EP3104873B1 (en) 2014-02-13 2019-09-04 Technische Universität München Fgf-8 for use in treating diseases or disorders of energy homeostasis
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016172187A1 (en) * 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to kras inhibitors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US9957325B2 (en) * 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
US10604558B2 (en) * 2016-01-05 2020-03-31 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
CN105837665B (zh) * 2016-05-16 2019-04-30 江苏大学 特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3556766B1 (en) * 2016-12-16 2024-07-31 Avixgen Inc. Use of a cell membrane penetrating peptide and intracellular delivery carrier including the same
WO2018111051A1 (ko) * 2016-12-16 2018-06-21 (주)에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR101933217B1 (ko) * 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
JP7374502B2 (ja) 2018-05-03 2023-11-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
WO2019240431A1 (ko) * 2018-06-14 2019-12-19 (주) 에빅스젠 세포 투과 펩티드 및 rpe65의 융합 단백질을 포함하는 레버 선천성 흑암시 치료용 약학적 조성물
EP3808762A4 (en) 2018-06-14 2022-03-30 Avixgen Inc. FUSION PROTEIN BOUND TO CELL PERMEABLE PEPTIDE AND COMPOSITION CONTAINING FUSION PROTEIN OR CELL PERMEABLE PEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVE INGREDIENTS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN115667302A (zh) 2020-02-06 2023-01-31 亚洲大学校产学协力团 将抗原衍生t细胞抗原表位或含所述表位的肽呈递到细胞表面的融合抗体及含所述融合抗体的组合物
CA3176046A1 (en) * 2020-05-04 2021-11-11 Michael C. BASSIK Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
US20230257429A1 (en) * 2020-07-13 2023-08-17 National University Of Singapore Peptide adjuvant for its therapeutic applications in viral and tumour vaccine development and cancer immunotherapy and autoimmune disease diagnosis and treatments
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用
EP4711380A1 (en) * 2024-09-16 2026-03-18 Fundació Institut Hospital del Mar d'Investigacions Mèdiques Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) * 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
JP2012525146A (ja) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX

Similar Documents

Publication Publication Date Title
JP2015512246A5 (https=)
Kinzler et al. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome
AU2007255196B2 (en) FKBP-L and uses thereof
JP2020178689A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2022078262A (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
CN101305020B (zh) 用于诊断和治疗的肿瘤相关抗原的鉴定
JP2003511071A (ja) Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター
TW201406959A (zh) 抗發炎胜肽及包含其之成分（三）
WO2014046481A1 (ko) 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
US8030455B2 (en) Pancreatic cancer genes
KR102060411B1 (ko) 세포 침투성 펩타이드, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
CN106279423B (zh) Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用
KR20190013612A (ko) 인간 항-antxr 키메라 항원 수용체 및 이의 용도
WO1999016790A1 (en) Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
KR101559974B1 (ko) ｓｉＲＮＡ 전달을 위한 재조합 단백질 및 이를 포함하는 조성물
US20210292390A1 (en) Chimeric antigen receptors
US9683025B2 (en) Methods and compositions for treating cancer and inflammatory diseases
KR102307567B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN108948203A (zh) 抗pd-1单克隆抗体及其制备方法和应用
CN101142233A (zh) 抑制cathelin样蛋白hCAP18/LL-17的试剂
CN101550185A (zh) 新的肿瘤相关基因或蛋白及其应用
EP1760087B1 (en) Novel protein complex and use thereof
US20040138161A1 (en) Methods of modulating proliferative conditions
CN118184743A (zh) 一种源于海洋动物的细胞膜穿透剂及其应用
Liu et al. Carrier-free, CXCR4-targeting RNA-Protein Nanoplexes for Polarizing Macrophages to Tumor Suppressors